Tale of Two Drugs: Wegovy Linked to Higher Risk of Blinding Eye Stroke vs Ozempic
https://www.profitableratecpm.com/f4ffsdxe?key=39b1ebce72f3758345b2155c98e6709c
(MedPage Today) — The obesity drug semaglutide (Wegovy) confers a significantly higher risk of ischemic optic neuropathy (ION) than any other GLP-1 agonist, including the diabetes semaglutide (Ozempic), an analysis of FDA data showed. In a…
